LUCD Lucid Diagnostics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LUCD

Price (delayed)

$1

Market cap

$203.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.45

Enterprise value

$201.99M

?
Relative Growth: Rel. Growth: 69
Relative Strength: Rel. Strength: 18
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 8

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, ...

Highlights
The EPS has surged by 62% year-on-year and by 35% since the previous quarter
The gross margin has surged by 54% year-on-year and by 25% since the previous quarter
Lucid Diagnostics's equity has soared by 174% YoY but it has plunged by 63% from the previous quarter
The quick ratio is up by 41% year-on-year but it has declined by 22% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: https://www.luciddx.com
Peers: ABT ISRG SYK BSX

Key stats

What are the main financial stats of LUCD

LUCD stock price

How has the Lucid Diagnostics stock price performed over time
Intraday
-0.5%
1 week
-4.76%
1 month
-8.26%
1 year
-18.03%
YTD
-8.26%
QTD
-13.04%

Financial performance

How have Lucid Diagnostics's revenue and profit performed over time
Revenue
$5.13M
Gross profit
-$1.61M
Operating income
-$49.27M
Net income
-$45.01M
Gross margin
-31.4%
Net margin
-876.7%
The gross margin has surged by 54% year-on-year and by 25% since the previous quarter
LUCD's gross profit is up by 43% year-on-year and by 18% since the previous quarter
Lucid Diagnostics's net margin has increased by 41% YoY and by 29% QoQ
The company's net income rose by 27% YoY and by 22% QoQ

Price vs fundamentals

How does LUCD's price correlate with its fundamentals

Growth

What is Lucid Diagnostics's growth rate over time

Valuation

What is Lucid Diagnostics stock price valuation
P/E
N/A
P/B
44.24
P/S
27.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
39.34
The EPS has surged by 62% year-on-year and by 35% since the previous quarter
Lucid Diagnostics's equity has soared by 174% YoY but it has plunged by 63% from the previous quarter
LUCD's P/B is 110% above its last 4 quarters average of 21.2
The price to sales (P/S) is 56% lower than the 5-year quarterly average of 61.7 but 3.5% higher than the last 4 quarters average of 26.5
LUCD's revenue is up by 23% year-on-year and by 9% since the previous quarter

Efficiency

How efficient is Lucid Diagnostics business performance
The return on equity has surged by 62% year-on-year and by 33% since the previous quarter
The return on sales has increased by 41% year-on-year and by 29% since the previous quarter
The ROA has increased by 41% YoY and by 18% from the previous quarter
Lucid Diagnostics's return on invested capital has decreased by 16% YoY but it has increased by 11% QoQ

Dividends

What is LUCD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LUCD.

Financial health

How did Lucid Diagnostics financials performed over time
Lucid Diagnostics's total assets is 13% higher than its total liabilities
Lucid Diagnostics's current ratio has increased by 43% YoY but it has decreased by 18% from the previous quarter
The quick ratio is up by 41% year-on-year but it has declined by 22% since the previous quarter
The debt to equity has soared by 184% QoQ
Lucid Diagnostics's equity has soared by 174% YoY but it has plunged by 63% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.